SV2018005621A - Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h - Google Patents

Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h

Info

Publication number
SV2018005621A
SV2018005621A SV2018005621A SV2018005621A SV2018005621A SV 2018005621 A SV2018005621 A SV 2018005621A SV 2018005621 A SV2018005621 A SV 2018005621A SV 2018005621 A SV2018005621 A SV 2018005621A SV 2018005621 A SV2018005621 A SV 2018005621A
Authority
SV
El Salvador
Prior art keywords
idh1
muted
inhibitor
aduct
isocitrate
Prior art date
Application number
SV2018005621A
Other languages
English (en)
Inventor
Heiko Schirmer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SV2018005621A publication Critical patent/SV2018005621A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

LA PRESENTE INVENCIÓN SE REFIERE AL ÁCIDO ADUCTIVO (2E)-BUT-2-ENEDIOICO Y ÁCIDO 3-(2-{[4-(TRIFLUOROMETOXI)FENIL]AMINO }-1-[( 1R,5R)-3, 3, 5- TRIMETILCICLOHEXIL] -1 H-BENZIMIDAZOL-5- IL)PROPANOICO (1 :4), A MÉTODOS PARA PREPARAR ESTE ADUCTO, COMPOSICIONES QUE COMPRENDEN ESTE ADUCTO Y, TAMBIÉN AL USO DE ESTE ADUCTO PARA PREPARAR UN MEDICAMENTO PARA EL TRATAMIENTO DE UNA ENFERMEDAD.
SV2018005621A 2015-07-27 2018-01-26 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h SV2018005621A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15178419 2015-07-27

Publications (1)

Publication Number Publication Date
SV2018005621A true SV2018005621A (es) 2018-12-05

Family

ID=53758092

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2018005621A SV2018005621A (es) 2015-07-27 2018-01-26 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h

Country Status (26)

Country Link
US (1) US10344004B2 (es)
EP (1) EP3328837B1 (es)
JP (1) JP6804516B2 (es)
KR (1) KR20180030789A (es)
CN (1) CN107810181B (es)
AR (1) AR105493A1 (es)
AU (1) AU2016300980B2 (es)
BR (1) BR112018001534A2 (es)
CA (1) CA2993473A1 (es)
CL (1) CL2018000249A1 (es)
CO (1) CO2018000793A2 (es)
CR (1) CR20180053A (es)
CU (1) CU20180014A7 (es)
DO (1) DOP2018000027A (es)
EA (1) EA201890386A1 (es)
EC (1) ECSP18006465A (es)
ES (1) ES2860693T3 (es)
HK (1) HK1252449A1 (es)
IL (1) IL256024A (es)
MX (1) MX2018001205A (es)
NI (1) NI201800014A (es)
PE (1) PE20181038A1 (es)
SV (1) SV2018005621A (es)
TN (1) TN2018000038A1 (es)
TW (1) TW201708193A (es)
WO (1) WO2017016992A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3105210B1 (en) 2014-02-11 2019-01-30 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
CA2939026A1 (en) 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
EP3209660B1 (en) 2014-10-23 2020-06-17 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors
CN107810176B (zh) 2015-06-08 2020-10-16 德国癌症研究公共权益基金会 作为mIDH1抑制剂的N-薄荷基苯并咪唑类化合物
EP3319945B1 (en) 2015-07-07 2021-04-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
EP3322694B1 (en) 2015-07-16 2020-02-19 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as midh1 inhibitors
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法
WO2019015672A1 (zh) * 2017-07-21 2019-01-24 南京明德新药研发股份有限公司 吡啶并咪唑类化合物及其应用
US20210113598A1 (en) * 2017-08-01 2021-04-22 Deutsches Krebsforschungszentrum (DKFZ) Stiftung des öffentlichen Rechts Combination of MIDH1 Inhibitors and DNA Hypomethylating Agents (HMA)
CN108948205B (zh) * 2018-07-13 2021-09-28 北京金岱生物科技有限公司 抗idh1r132h单克隆抗体及其应用
TWI760017B (zh) * 2019-12-23 2022-04-01 大陸商昆藥集團股份有限公司 一種ｉｄｈ１突變體抑制劑的鹽型、晶型及其製備方法
CA3189348A1 (en) 2020-07-21 2022-01-27 Daiichi Sankyo Company, Limited Combination pharmaceutical of temozolomide and mutant idh1 enzyme inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125901B2 (en) * 2009-06-23 2015-09-08 The Translational Genomics Research Institute 4-(benzimidazol-2-ylamino)benzamide derivatives and salts or solvates thereof
EA024026B1 (ru) * 2010-11-25 2016-08-31 Рациофарм Гмбх Новые соли и полиморфные формы афатиниба
CA2849995A1 (en) * 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EP3105210B1 (en) * 2014-02-11 2019-01-30 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
CA2939026A1 (en) * 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
ES2822654T3 (es) 2014-10-23 2021-05-04 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Benzimidazol-2-aminas como inhibidores de mIDH1
EP3209660B1 (en) * 2014-10-23 2020-06-17 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors
CN107810176B (zh) * 2015-06-08 2020-10-16 德国癌症研究公共权益基金会 作为mIDH1抑制剂的N-薄荷基苯并咪唑类化合物
EP3319945B1 (en) 2015-07-07 2021-04-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
EP3322694B1 (en) * 2015-07-16 2020-02-19 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as midh1 inhibitors
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法

Also Published As

Publication number Publication date
AR105493A1 (es) 2017-10-11
IL256024A (en) 2018-01-31
US10344004B2 (en) 2019-07-09
AU2016300980B2 (en) 2020-12-24
ECSP18006465A (es) 2018-04-30
DOP2018000027A (es) 2018-02-28
NI201800014A (es) 2018-09-06
KR20180030789A (ko) 2018-03-26
AU2016300980A1 (en) 2017-12-21
CL2018000249A1 (es) 2018-07-06
JP6804516B2 (ja) 2020-12-23
US20180222870A1 (en) 2018-08-09
WO2017016992A1 (en) 2017-02-02
HK1252449A1 (zh) 2019-05-24
MX2018001205A (es) 2018-04-24
ES2860693T3 (es) 2021-10-05
EA201890386A1 (ru) 2018-08-31
TN2018000038A1 (en) 2019-07-08
EP3328837B1 (en) 2021-01-06
CN107810181A (zh) 2018-03-16
CA2993473A1 (en) 2017-02-02
BR112018001534A2 (pt) 2018-09-11
JP2018521095A (ja) 2018-08-02
CO2018000793A2 (es) 2018-05-10
PE20181038A1 (es) 2018-07-03
CN107810181B (zh) 2021-06-22
CU20180014A7 (es) 2018-06-05
TW201708193A (zh) 2017-03-01
EP3328837A1 (en) 2018-06-06
CR20180053A (es) 2018-03-20

Similar Documents

Publication Publication Date Title
SV2018005621A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
EA201790398A1 (ru) Способы лечения заболевания печени
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
EA201691421A1 (ru) Гетероарилы и их применение
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
EA201692437A1 (ru) Комбинация
CO2018003224A2 (es) Formulaciones de aminoacidos de liberacion modificada administradas oralmente
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
MX2017002610A (es) INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
ECSP14027694A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
BR112018014247A2 (pt) inibição de reação alérgica usando um inibidor il-33
MX2019012952A (es) Composiciones parasiticidas que comprenden derivados de indol, metodos y usos de los mismos.
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
EA201600012A1 (ru) Способ профилактики и/или лечения сердечно-сосудистых заболеваний
EA201591899A1 (ru) Введение nsaid и соответствующие композиции, способы и системы
CU20140133A7 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido